Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder
NCT07249554Phase 2Not yet recruiting
- Sponsor
- Johns Hopkins University
- Start
- Nov 2026
- Primary completion
- Jul 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in alcohol use disorder (AUD), sponsored by Johns Hopkins University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07249554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249554.